Vascular Endothelial Growth Factor Antibodies Market By Type (Bevacizumab, Ranibizumab, Aflibercept), By Therapeutic Area (Cancer Treatment, Age-Related Macular Degeneration, Diabetic Retinopathy), By Administration Route (Intravenous, Intravitreal, Subcutaneous), By End-Use (Hospitals, Clinics, Research Laboratories), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Vascular Endothelial Growth Factor Antibodies Market was valued at USD 2.1 billion in 2024-e and will surpass USD 4.3 billion by 2030; growing at a CAGR of 12.2% during 2025 - 2030.

The vascular endothelial growth factor (VEGF) antibodies market is witnessing significant growth, driven by the increasing prevalence of conditions that require VEGF inhibition for effective treatment. VEGF is a critical protein involved in the growth of blood vessels, and its inhibition has become a pivotal therapeutic approach in the treatment of various cancers and retinal disorders. The market for VEGF antibodies has expanded with the approval of several monoclonal antibodies, which are used in treating a range of diseases where abnormal blood vessel growth plays a role.

With advancements in biotechnology and the growing understanding of VEGF's role in disease progression, the demand for VEGF-targeted therapies is rapidly increasing. The market is poised to continue expanding, with the rise in chronic conditions like cancer, diabetic retinopathy, and age-related macular degeneration (AMD), which further drives the adoption of these antibodies. The development of newer, more effective treatments that target VEGF is expected to keep this market in a growth trajectory.

Bevacizumab Is the Largest Segment Owing to Its Broad Applications in Cancer Treatment

Bevacizumab is the largest segment in the VEGF antibodies market, largely due to its broad applications in cancer treatment. Approved for use in treating multiple cancers, including colorectal cancer, lung cancer, and glioblastoma, bevacizumab works by inhibiting VEGF, thereby blocking the formation of blood vessels that tumors need to grow. Its efficacy in slowing down tumor growth and reducing the risk of metastasis has made it a cornerstone of oncology treatments.

The widespread use of bevacizumab across various cancer types has driven its dominance in the market. Its ability to improve patient outcomes by controlling tumor progression and enhancing the effectiveness of chemotherapy has established it as a first-line treatment in many cancer protocols. As the global incidence of cancer continues to rise, the demand for bevacizumab is expected to remain strong, ensuring its position as the leading product in the VEGF antibodies market.

Cancer Treatment Is the Largest Therapeutic Area Owing to the Increasing Prevalence of Cancer

Cancer treatment is the largest therapeutic area within the VEGF antibodies market, primarily due to the increasing prevalence of cancer worldwide. The ability of VEGF antibodies, particularly bevacizumab, to inhibit tumor angiogenesis makes them a vital part of modern cancer therapy. These antibodies are used in combination with chemotherapy and other treatments to target the vascular network supporting tumors, thereby improving treatment outcomes and extending patient survival.

As the global cancer burden continues to rise, the demand for targeted therapies like VEGF inhibitors is also expected to increase. With innovations in combination therapies and new indications for VEGF-targeted treatments, the cancer treatment segment is expected to maintain its dominant position in the VEGF antibodies market.

Intravenous Administration Is the Largest Route of Administration Owing to Its Established Efficacy in Systemic Treatment

Intravenous administration is the largest route of administration in the VEGF antibodies market, owing to its established efficacy in delivering systemic treatment for conditions like cancer and age-related macular degeneration (AMD). Intravenous administration allows the medication to enter the bloodstream directly, providing rapid and widespread distribution throughout the body, which is crucial for treating systemic diseases such as cancer.

The preference for intravenous administration is also driven by its long track record of success in clinical settings, particularly for cancer treatments where high doses of VEGF antibodies are required to achieve therapeutic efficacy. This route of administration is expected to remain the dominant method, especially as new indications for VEGF inhibitors continue to emerge, further fueling the demand for intravenous therapies.

Hospitals Are the Largest End-Use Industry Owing to High Patient Volume and Specialized Treatment Requirements

Hospitals represent the largest end-use industry in the VEGF antibodies market, driven by their high patient volume and the specialized treatment capabilities required for administering VEGF inhibitors. Hospitals are the primary settings for the treatment of conditions like cancer and AMD, where VEGF antibodies are commonly used. With specialized oncology and ophthalmology departments, hospitals are equipped with the necessary infrastructure and expertise to provide these advanced therapies to patients.

The role of hospitals as the leading end-use industry is reinforced by the demand for highly skilled healthcare professionals and advanced imaging technologies to monitor and administer VEGF-targeted treatments effectively. As the number of patients requiring cancer treatments and retinal therapies grows, hospitals will continue to dominate the VEGF antibodies market, ensuring widespread access to these critical therapies.

North America Leads the Market Owing to Advanced Research Capabilities and High Adoption of Targeted Therapies

North America leads the vascular endothelial growth factor (VEGF) antibodies market, primarily driven by the region’s advanced research capabilities and the high adoption of targeted therapies in cancer treatment and age-related macular degeneration (AMD). The United States, in particular, is at the forefront, with widespread use of VEGF inhibitors such as Bevacizumab, Ranibizumab, and Aflibercept in both oncology and ophthalmology. The region's established healthcare infrastructure and high healthcare expenditure further contribute to the rapid adoption of these innovative therapies.

Moreover, strong collaboration between biotech companies and research institutions in North America has accelerated the development of new VEGF-targeted therapies. The growing number of FDA approvals and the rising demand for biologic therapies in cancer treatment and retinal diseases solidify North America’s leadership in the VEGF antibodies market.

Leading Companies and Competitive Landscape

The VEGF antibodies market is highly competitive, with several key players dominating the sector, including Roche, Novartis, and Bayer. These companies are at the forefront of developing and marketing VEGF-targeted therapies such as bevacizumab, ranibizumab, and aflibercept. With extensive research and development investments, these companies aim to expand the therapeutic indications for their products and enhance treatment efficacy.

The competitive landscape is shaped by the continuous evolution of biotechnology, with new entrants and smaller biotech firms also making significant strides in the VEGF inhibitors market. Partnerships, collaborations, and licensing agreements are common in this industry as companies seek to leverage each other's strengths to improve their product offerings. As innovation in targeted therapies continues, leading companies are well-positioned to maintain their leadership in the VEGF antibodies market, offering patients more effective treatments for a wide range of conditions.

Recent Developments:

• In December 2024, Roche announced the launch of a new VEGF antibody formulation designed for more efficient treatment of cancer. This innovation aims to reduce treatment cycles and improve patient outcomes.
• In November 2024, Regeneron Pharmaceuticals expanded its portfolio with a new VEGF inhibitor for treating diabetic retinopathy. The new drug is expected to provide more effective results with fewer side effects.
• In October 2024, Novartis received FDA approval for a new intravitreal administration method for their VEGF antibody, improving patient compliance. This method allows for less frequent injections and better patient adherence.
• In September 2024, Amgen entered into a collaboration with a biotech firm to develop next-generation VEGF antibodies for cancer therapy. The partnership aims to deliver more personalized treatment options.
• In August 2024, AbbVie launched a biosimilar version of Bevacizumab, making it more accessible to patients in emerging markets. This development aims to reduce treatment costs and increase access to life-saving therapies.

List of Leading Companies:

• Roche
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Amgen
• AbbVie
• Eli Lilly and Company
• Bayer
• Merck & Co.
• Boehringer Ingelheim
• GSK
• Sanofi
• AstraZeneca
• Celltrion
• Teva Pharmaceutical Industries

Report Scope: